Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.

被引：0
|
作者：
Leone, Jose Pablo
Cole, Bernard F.
Regan, Meredith M.
Thurlimann, Beat J. K.
Coates, Alan S.
Goldhirsch, Aron
Di Leo, Angelo
Colleoni, Marco
Luis, Ines Maria Vaz Duarte
Lin, Nancy U.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Vermont, Burlington, VT USA
[3] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[4] Kantonsspital, St Gallen, Switzerland
[5] Univ Sydney, Sydney, NSW, Australia
[6] IBCSG Investigator, Bern, Switzerland
[7] SOLE Investigator, Bern, Switzerland
[8] Hosp Prato, Prato, Italy
[9] European Inst Oncol, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
538
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
    Leone, Jose P.
    Cole, Bernard F.
    Regan, Meredith M.
    Thurlimann, Beat
    Coates, Alan S.
    Rabaglio, Manuela
    Giobbie-Hurder, Anita
    Gelber, Richard D.
    Ejlertsen, Bent
    Harvey, Vernon J.
    Neven, Patrick
    Lang, Istvan
    Bonnefoi, Herve
    Wardley, Andrew
    Goldhirsch, Aron
    Di Leo, Angelo
    Colleoni, Marco
    Vaz-Luis, Ines
    Lin, Nancy U.
    CANCER, 2021, 127 (05) : 700 - 708
  • [2] PREDICTORS OF HYPERTENSION IN IBCSG 18-98/BIG 1-98: ADJUVANT THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, EARLY BREAST CANCER
    Rabaglio-Poretti, M.
    Giobbie-Hurder, A.
    Thuerlimann, B.
    Regan, M.
    Ejlertsen, B.
    Debled, M.
    Colleoni, M.
    Goldhirsch, A.
    Coates, A.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Regan, Meredith M.
    Price, Karen N.
    Giobbie-Hurder, Anita
    Thuerlimann, Beat
    Gelber, Richard D.
    BREAST CANCER RESEARCH, 2011, 13 (03)
  • [4] Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Meredith M Regan
    Karen N Price
    Anita Giobbie-Hurder
    Beat Thürlimann
    Richard D Gelber
    Breast Cancer Research, 13
  • [5] Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
    Giobbie-Hurder, Anita
    Price, Karen N.
    Gelber, Richard D.
    CLINICAL TRIALS, 2009, 6 (03) : 272 - 287
  • [6] Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
    Mauriac, L.
    Keshaviah, A.
    Debled, M.
    Mouridsen, H.
    Forbes, J. F.
    Thuerlimann, B.
    Paridaens, R.
    Monnier, A.
    Lang, I.
    Wardley, A.
    Nogaret, J.-M.
    Gelber, R. D.
    Castiglione-Gertsch, M.
    Price, K. N.
    Coates, A. S.
    Smith, I.
    Viale, G.
    Rabaglio, M.
    Zabaznyi, N.
    Goldhirsch, A.
    ANNALS OF ONCOLOGY, 2007, 18 (05) : 859 - 867
  • [7] Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
    Bracken-Clarke, Dara B.
    Lucas, Mairi W.
    Higgins, Michaela J.
    BREAST CARE, 2017, 12 (03) : 138 - 144
  • [8] DESIGN AND EVOLUTION OF BIG 1-98: A RANDOMIZED, DOUBLE-BLIND, PHASE-III STUDY COMPARING LETROZOLE AND TAMOXIFEN AS ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH RECEPTOR-POSITIVE, EARLY BREAST CANCER - BIG 1-98 COLLABORATIVE AND INTERNATIONAL BREAST CANCER STUDY GROUPS
    Giobbie-Hurder, A. E.
    Gelber, R. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 80 - 80
  • [9] Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Update of the BIG 1-98 primary core analysis
    Thuerlimann, B.
    BREAST, 2009, 18 : S60 - S60
  • [10] A review of the BIG results: the Breast International Group 1-98 trial analyses
    Doughty, J. C.
    BREAST, 2008, 17 : S9 - S14
12345